How long should physicians follow up with patients after curative treatment for hepatocellular carcinoma?
作者信息
Kim Bo Hyun
机构信息
Division of Gastroenterology, Department of Internal Medicine, Center for Liver and Pancreatobiliary Cancer, National Cancer Center, Goyang, Korea.
出版信息
Clin Mol Hepatol. 2020 Oct;26(4):579-581. doi: 10.3350/cmh.2020.0200. Epub 2020 Sep 23.
Abstract
摘要
相似文献
1
How long should physicians follow up with patients after curative treatment for hepatocellular carcinoma?肝细胞癌根治性治疗后，医生应随访患者多长时间？
Clin Mol Hepatol. 2020 Oct;26(4):579-581. doi: 10.3350/cmh.2020.0200. Epub 2020 Sep 23.
2
Predictors of extrahepatic recurrence after curative hepatectomy for hepatocellular carcinoma.根治性肝切除术后肝细胞癌肝外复发的预测因素。
Ann Surg Oncol. 2010 Oct;17(10):2740-6. doi: 10.1245/s10434-010-1076-2. Epub 2010 Apr 22.
3
[Different prognostic factors are associated with early and late intrahepatic recurrence following curative hepatectomy for patients with hepatocellular carcinoma].[不同的预后因素与肝细胞癌患者根治性肝切除术后早期和晚期肝内复发相关]
Zhonghua Wai Ke Za Zhi. 2010 Jun 1;48(11):806-11.
4
Analysis of prognostic factors affecting survival after initial recurrence and treatment efficacy for recurrence in patients undergoing potentially curative hepatectomy for hepatocellular carcinoma.对接受潜在根治性肝切除术治疗肝细胞癌的患者首次复发后的生存预后因素及复发治疗效果的分析。
Ann Surg Oncol. 2007 Aug;14(8):2337-47. doi: 10.1245/s10434-007-9415-7. Epub 2007 May 15.
5
Repeat hepatectomy is the most useful treatment for recurrent hepatocellular carcinoma.肝切除术后复发的肝细胞癌，再次肝切除术是最有效的治疗方法。
J Hepatobiliary Pancreat Surg. 2001;8(5):410-6. doi: 10.1007/s005340100002.
6
Aurora kinase B is a predictive factor for the aggressive recurrence of hepatocellular carcinoma after curative hepatectomy.极光激酶B是肝细胞癌根治性肝切除术后侵袭性复发的一个预测因素。
Br J Surg. 2008 May;95(5):611-9. doi: 10.1002/bjs.6011.
7
Risk factors and patterns of early recurrence after curative hepatectomy for hepatocellular carcinoma.肝细胞癌根治性肝切除术后的早期复发危险因素及模式
Surg Oncol. 2016 Mar;25(1):24-9. doi: 10.1016/j.suronc.2015.12.002. Epub 2015 Dec 12.
8
Resection of metachronous hepatocellular carcinomas.异时性肝细胞癌切除术
South Med J. 1986 Dec;79(12):1578-82. doi: 10.1097/00007611-198612000-00025.
9
Clinicopathological features of recurrence in patients after 10-year disease-free survival following curative hepatic resection of hepatocellular carcinoma.根治性肝切除术后 10 年无瘤生存患者复发的临床病理特征。
World J Surg. 2013 Apr;37(4):820-8. doi: 10.1007/s00268-013-1902-3.
10
Imaging of hepatocellular carcinoma recurrence post liver resection: a pictorial essay.肝切除术后肝细胞癌复发的影像学表现：图文综述
J Med Imaging Radiat Oncol. 2013 Jun;57(3):337-44. doi: 10.1111/j.1754-9485.2012.02468.x. Epub 2012 Oct 29.
引用本文的文献
1
Cause of death and cause-specific mortality for primary liver cancer in South Korea: A nationwide population-based study in hepatitis B virus-endemic area.韩国原发性肝癌的死因和死因特异性死亡率：乙型肝炎病毒流行地区的全国性基于人群的研究。
Clin Mol Hepatol. 2022 Apr;28(2):242-253. doi: 10.3350/cmh.2021.0355. Epub 2022 Feb 7.
2
Metformin and Dichloroacetate Suppress Proliferation of Liver Cancer Cells by Inhibiting mTOR Complex 1.二甲双胍和二氯乙酸通过抑制 mTOR 复合物 1 抑制肝癌细胞增殖。
Int J Mol Sci. 2021 Sep 17;22(18):10027. doi: 10.3390/ijms221810027.
3
Diagnostic performance of the LR-M criteria and spectrum of LI-RADS imaging features among primary hepatic carcinomas.LR-M 标准与原发性肝癌 LI-RADS 成像特征谱的诊断性能。
Abdom Radiol (NY). 2020 Nov;45(11):3743-3754. doi: 10.1007/s00261-020-02562-y.
本文引用的文献
1
Substantial risk of recurrence even after 5 recurrence-free years in early-stage hepatocellular carcinoma patients.即使在早期肝细胞癌患者无复发 5 年后，仍存在复发的重大风险。
Clin Mol Hepatol. 2020 Oct;26(4):516-528. doi: 10.3350/cmh.2020.0016. Epub 2020 Sep 11.
2
A global view of hepatocellular carcinoma: trends, risk, prevention and management.全球视角下的肝细胞癌：趋势、风险、预防与管理。
Nat Rev Gastroenterol Hepatol. 2019 Oct;16(10):589-604. doi: 10.1038/s41575-019-0186-y. Epub 2019 Aug 22.
3
Liver Resection for Nonalcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma.肝切除术治疗非酒精性脂肪性肝病相关肝细胞癌。
J Am Coll Surg. 2019 Nov;229(5):467-478.e1. doi: 10.1016/j.jamcollsurg.2019.07.012. Epub 2019 Aug 6.
4
2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma.2018 韩国肝癌协会-韩国国家癌症中心肝细胞癌管理实践指南。
Gut Liver. 2019 May 15;13(3):227-299. doi: 10.5009/gnl19024.
5
Liver Resection for Hepatocellular Carcinoma in Non-alcoholic Fatty Liver Disease: a Multicenter Propensity Matching Analysis with HBV-HCC.非酒精性脂肪性肝病肝细胞癌的肝切除术：与 HBV-HCC 的多中心倾向评分匹配分析。
J Gastrointest Surg. 2020 Feb;24(2):320-329. doi: 10.1007/s11605-018-04071-2. Epub 2019 Jan 7.
6
Nonalcoholic fatty liver disease-associated hepatocellular carcinoma in a hepatitis B virus-endemic area.乙肝病毒高流行地区的非酒精性脂肪性肝病相关肝细胞癌
Eur J Gastroenterol Hepatol. 2018 Sep;30(9):1090-1096. doi: 10.1097/MEG.0000000000001174.
7
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases.肝细胞癌的诊断、分期及管理：美国肝病研究协会2018年实践指南
Hepatology. 2018 Aug;68(2):723-750. doi: 10.1002/hep.29913.
8
Temporal trends, clinical patterns and outcomes of NAFLD-related HCC in patients undergoing liver resection over a 20-year period.20年间接受肝切除手术的非酒精性脂肪性肝病相关肝癌患者的时间趋势、临床模式及预后
Aliment Pharmacol Ther. 2017 Nov;46(9):856-863. doi: 10.1111/apt.14261. Epub 2017 Aug 31.
9
Surveillance after curative treatment for colorectal cancer.结直肠癌治愈性治疗后的监测。
Nat Rev Clin Oncol. 2017 May;14(5):297-315. doi: 10.1038/nrclinonc.2016.199. Epub 2016 Dec 20.
10
Survival analysis after liver resection for hepatocellular carcinoma: A consecutive cohort of 1002 patients.肝细胞癌肝切除术后的生存分析：1002例连续队列患者。
J Gastroenterol Hepatol. 2017 May;32(5):1055-1063. doi: 10.1111/jgh.13632.
Zotero 插件